New Developments in Liposomal Drug Delivery


Authors: Pattni BS, Chupin VV, Torchilin VP

Journal: Chemical Reviews

DOI: 10.1021/acs.chemrev.5b00046

Publication - Abstract

October 14, 2015

Abstract:


Described first in the 1960s by Bangham1 and understood as a potential drug delivery system in the early 1970s,2−4 the liposome has since become integral to research and clinical applications in the field of nanomedicine. Five decades of research in the field of liposome research have shown their prospective benefits in the medical and cosmetic5−7 as well as the food industry.8,9 Several promising small molecule drugs and genes previously deemed less than useful due to problems of stability, solubility, and nonspecific toxicity can now be delivered to the intended sites of action with the help of nanocarriers like micelles, nanoparticles, and liposomes.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Blog Posts
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Lipid nanoparticles (LNPs) for drug-delivery applications are largely derived from natural lipids. Synthetic lipids, particularly those incorporating branched hydrocarbons and hyper-branched hydrocarbon architectures, may afford enhanced lipophilic...

Read More


Publication - Abstract

Harnessing RNAi-Based Nanomedicines for Therapeutic Gene Silencing in B-cell Malignancies

Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D, Goldsmith M, Abraham A, Benjamini O, Bairey O, Raanani P,Nagler A, Lieberman J, Peer D

Despite progress in systemic small interfering RNA (siRNA) delivery to the liver and to solid tumors, systemic siRNA delivery to leukocytes remains challenging. The ability to silence gene expression in leukocytes has great potential for ...

Read More


Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
X